ICAM1 and acute lymphoblastic leukemia: Notably, blockade of ICAM-1 and VCAM-1 significantly reduced myeloid-mediated sensitization of T-ALL cells to IGF1, demonstrating that integrin activation is required for the full responsiveness of T-ALL cells to IGF1.